Among dogs that did not receive adjunctive therapy after surgery, was Beclin-1 a significant prognostic marker?

• A. Yes
• B. Not evaluated
• C. No
• D. Only in dermal tumors

Answer: (C)

Beclin-1 as a marker relates to autophagy, a process that can help or hinder tumor cells depending on context. The question specifically asks whether Beclin-1 levels predicted outcome in dogs that did not receive any adjunctive therapy after surgery. In that subgroup, the study did not find a statistically significant association between Beclin-1 expression and prognosis, meaning Beclin-1 did not reliably distinguish good from poor outcomes on its own when no additional treatment was given.

This can happen because, without adjuvant therapy, the natural course of the tumor is more strongly dictated by factors like surgical margins, tumor grade, stage, and host biology, which can overwhelm any modest prognostic signal from Beclin-1. Also, limitations such as sample size, variability in measuring Beclin-1 (for example, how expression is quantified and categorized), and tumor heterogeneity can reduce the power to detect an effect. It’s possible that Beclin-1 might still have prognostic value in other contexts (different tumor types, sites, or in combination with treatments), but in this particular scenario the data did not show a significant prognostic role.